Search Result

Results for "

Modifier

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Apoptosis (1) Autophagy (5) Biochemical Assay Reagents (8) CRISPR/Cas9 (1) DNA-PK (2) DNA/RNA Synthesis (6) Drug-Linker Conjugates for ADC (4) E1/E2/E3 Enzyme (5) Endogenous Metabolite (6) Epigenetic Reader Domain (1) Gap Junction Protein (2) Histone Demethylase (4) Histone Methyltransferase (2) HSV (5) Influenza Virus (1) Isotope-Labeled Compounds (4) MicroRNA (1) Microtubule/Tubulin (4) Mitochondrial Metabolism (4) Nucleoside Antimetabolite/Analog (1) P2X Receptor (1) PDI (1) PSMA (1) Reactive Oxygen Species (3) SARS-CoV (5) Sodium Channel (3) Taste Receptor (1) Toll-like Receptor (TLR) (5) Topoisomerase (1)
By Research Areas:	Cancer (32) Cardiovascular Disease (3) Infection (6) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (10)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111945

*Cys modifier* 1**	Others	Others
Cys modifier 1 (compound 7) is a cysteine-selective protein modifier for protein bioconjugation. A fluorescent carbonylacrylic derivative bearing nitrobenzofurazan (λ_ex=465nm and λ_em539 nm)_[1].

HY-N6653

Lentinan 2 Publications Verification	Others	Cancer
Lentinan is purified β-glucan from Shiitake mushrooms. Lentinan has been approved as a biological response modifier for gastric cancer in Japan .

HY-N7438

Mogroside VI A	Others	Others
Mogroside VI A, an isomer of Mogroside VI isolated from Luo Han Guo, exerts sweetness property. Mogroside VI A can be used for sweetener and/or taste modifier research .

HY-136572

CEM114	Epigenetic Reader Domain CRISPR/Cas9	Cancer
CEM114 is an effective chemical epigenetic modifier (CEM) that recruits endogenous chromatin machinery through CRISPR-Cas9 systems .

HY-W129456

Isaxonine	Others	Neurological Disease
Isaxonine acts as a modifier of the surface pH of the bilayer . Isaxonine accelerates the rate of peripheral nerve regeneration, stimulate axonal sprouting and promote motor and sensory function recovery . Isaxonine is a neurotrophic agent .

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-W015114

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-W250721D

Carbomer Carboxy polymethylene	Biochemical Assay Reagents	Others
Carbomer can be used as an excipient, such as Bioadhesives, emulsifiers, release modifiers, suspending agents, tablet binders, viscosity enhancers, etc. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .

HY-W250721E

Carbomer copolymer Carboxy polymethylene (copolymer)	Biochemical Assay Reagents	Others
Carbomer copolymer can be used as an excipient, such as Bioadhesives, emulsifiers, release modifiers, suspending agents, tablet binders, viscosity enhancers, etc. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .

HY-W250721F

Carbomer homopolymer Carboxy polymethylene (homopolymer)	Biochemical Assay Reagents	Others
Carbomer homopolymer can be used as an excipient, such as Bioadhesives, emulsifiers, release modifiers, suspending agents, tablet binders, viscosity enhancers, etc. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .

HY-W250721G

Carbomer interpolymer Carboxy polymethylene (interpolymer)	Biochemical Assay Reagents	Others
Carbomer interpolymer can be used as an excipient, such as Bioadhesives, emulsifiers, release modifiers, suspending agents, tablet binders, viscosity enhancers, etc. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .

HY-100241

Nafocare B1

Methylfurylbutyrolactone
Others Inflammation/Immunology

Nafocare B1 is a synthetic immune biological response modifier.

Nafocare B1 Methylfurylbutyrolactone	Others	Inflammation/Immunology
Nafocare B1 is a synthetic immune biological response modifier.

HY-18593

Mal-β-CD 6-O-alpha-D-Maltosyl-beta-cyclodextrin	Biochemical Assay Reagents	Others
Mal-β-CD is a cellular cholesterol modifier which can form soluble inclusion complex with cholesterol.

HY-101792

RG7800

5 Publications Verification

RO6885247
DNA/RNA Synthesis Others

RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.

RG7800 5 Publications Verification RO6885247	DNA/RNA Synthesis	Others
RG7800 is a SMN2 splicing modifier. RG7800 has the potential for spinal muscular atrophy treatment.

HY-10913A

Danegaptide Hydrochloride 1 Publications Verification GAP-134 Hydrochloride; ZP 1609 Hydrochloride	Gap Junction Protein	Cardiovascular Disease
Danegaptide Hydrochloride (GAP-134 Hydrochloride) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect .

HY-10913

Danegaptide GAP-134; ZP 1609	Gap Junction Protein	Cardiovascular Disease
Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect .

HY-153182

GBT1118

Others Cardiovascular Disease

GBT1118 is a potent and orally active allosteric modifier of hemoglobin oxygen affinity. GBT1118 increases tolerance to severe hypoxia .

GBT1118	Others	Cardiovascular Disease
GBT1118 is a potent and orally active allosteric modifier of hemoglobin oxygen affinity. GBT1118 increases tolerance to severe hypoxia .

HY-Y0873O

PEG35000 Polyethylene glycol 35000	Biochemical Assay Reagents	Others
PEG35000 is a polyethylene glycol with a molecular weight of 35,000 that can be used as a carrier material and modifier in drug delivery systems .

HY-13619

Efaproxiral 1 Publications Verification RSR13	Reactive Oxygen Species	Cancer
Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy .

HY-13619A

Efaproxiral sodium 1 Publications Verification RSR13 sodium	Reactive Oxygen Species	Cancer
Efaproxiral sodium (RSR13 sodium) is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.

HY-109101

Risdiplam 5+ Cited Publications RG7916; RO7034067	DNA/RNA Synthesis	Neurological Disease
Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed *SMN2* pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-15582

Auristatin E	Microtubule/Tubulin ADC Cytotoxin	Cancer
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin.

HY-145989

Aminobenzenesulfonic auristatin E	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-128899

MC-Val-Cit-PAB-Auristatin E	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-Auristatin E is a agent-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker MC-Val-Cit-PAB.

HY-113811

Diisopropyl xanthogen disulfide DIXDS; Diproxide	Others	Others
Diisopropyl xanthogen disulfide (DIXDS) is a superaccelerator for natural rubber and latex, styrene-butadiene rubber and latex, nitrile butadiene rubber and recycled rubber. It can also be used as a neoprene rubber modifier and an insoluble sulfur stabilizer .

HY-145989A

Aminobenzenesulfonic auristatin E TFA	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-N7075

Inulin 2 Publications Verification	Endogenous Metabolite	Metabolic Disease Cancer
Inulin is a storage polysaccharide and belongs to a group of non-digestible carbohydrates, fructan. Inulin is from plants of the Compositae and Lilialiaceaes families, often used as a prebiotic, fat replacer, sugar replacer, texture modifier, plays beneficial role in gastric .

HY-109101S

Risdiplam-d4	DNA/RNA Synthesis	Neurological Disease
Risdiplam-d₄ is deuterium labeled Risdiplam. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1].

HY-109101AS1

Risdiplam-hydroxylate-d3	Isotope-Labeled Compounds DNA/RNA Synthesis	Neurological Disease
Risdiplam-hydroxylate-d₃ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-109101AS2

Risdiplam-hydroxylate-d6	Isotope-Labeled Compounds DNA/RNA Synthesis	Neurological Disease
Risdiplam-hydroxylate-d₆ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-13619S

Efaproxiral-d6	Isotope-Labeled Compounds Reactive Oxygen Species	Cancer
Efaproxiral-d₆ is the deuterium labeled Efaproxiral. Efaproxiral (RSR13) is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy[1][2].

HY-B0180B

Imiquimod maleate Maximum Cited Publications 30 Publications Verification R 837 maleate	Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Inflammation/Immunology Cancer
Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180A

Imiquimod hydrochloride Maximum Cited Publications 30 Publications Verification R 837 hydrochloride	Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Inflammation/Immunology Cancer
Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180

Imiquimod Maximum Cited Publications 30 Publications Verification R 837	Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Inflammation/Immunology Cancer
Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-139662

HB007	E1/E2/E3 Enzyme	Cancer
HB007 is a *small ubiquitin-related modifier* 1 (SUMO1)** degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers .

HY-141510

myo-Inositol trispyrophosphate hexasodium ITPP hexasodium	Others	Cancer
myo-Inositol trispyrophosphate (ITPP) hexasodium, a modifier of haemoglobin, is an allosteric effector that reduces the oxygen‐binding affinity of haemoglobin and facilitates the release of oxygen by red blood cells. myo-Inositol trispyrophosphate can reverse hypoxia, control tumor growth and improve chemotherapy response .

HY-105336

3-Deazauridine NSC 126849	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Cancer
3-Deazauridine (NSC 126849) is a uridine analogue. 3-Deazauridine competitively inhibits cytidine triphosphate synthase to inhibit the biosynthesis of cytidine-5'-triphosphate. 3-Deazauridine acts synergistically with several antineoplastic agents, acting as a biological response modifier .

HY-145989S

Aminobenzenesulfonic auristatin E-d8	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].

HY-B0180S

Imiquimod-d6 R 837-d₆	Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Inflammation/Immunology Cancer
Imiquimod-d₆ is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

HY-B0180S1

Imiquimod-d9 R 837-d₉	Isotope-Labeled Compounds Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Inflammation/Immunology Cancer
Imiquimod-d₉ is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

HY-P5790

μ-TRTX-Hd1a	Sodium Channel	Neurological Disease
μ-TRTX-Hd1a, a spider venom, is a selective NaV 1.7 inhibitor. μ-TRTX-Hd1a is a gating modifier that inhibits human NaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II .

HY-158122

Lys(CO-C3-p-I-Ph)-O-tBu	DNA-PK	Cancer
Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules. Lys(CO-C3-p-I-Ph)-O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-158118

Lys(CO-C3-p-I-Ph)-OMe	DNA-PK	Cancer
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-136352

Adenosine 5'-succinate	Taste Receptor	Others
Adenosine 5'-succinate is a chemically AMP-related compound and potently inhibits Denatonium benzoate/taste receptor activation of transducin .

HY-112624B

Dextran (MW 70000)	Biochemical Assay Reagents	Others
Dextran (MW 70000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.

HY-112624C

Dextran (MW 40000)	Biochemical Assay Reagents Endogenous Metabolite	Others
Dextran (MW 40000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.

HY-100360

MS049	Histone Methyltransferase	Cancer
MS049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC₅₀s of 34 nM and 43 nM, respectively. MS049 reduces levels of Med12me2a and H3R2me2a in HEK293 cells. MS049 is not toxic and does not affect the growth of HEK293 cells .

HY-100360A

MS049 dihydrochloride	Histone Methyltransferase	Cancer
MS049 dihydrochloride is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC₅₀s of 34 nM and 43 nM, respectively. MS049 dihydrochloride reduces levels of Med12me2a and H3R2me2a in HEK293 cells. MS049 dihydrochloride is not toxic and does not affect the growth of HEK293 cells .

HY-P1218A

Phrixotoxin 3 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P1218

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

Cat. No.	Product Name

HY-L039

Reprogramming Compound Library

2048 compounds

Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.

MCE Reprogramming Compound Library contains a unique collection of 2048 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.

HY-L024

Histone Modification Research Compound Library

614 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 614 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6653

Lentinan 2 Publications Verification	Structural Classification Polysaccharides Classification of Application Fields Agaricaceae Source classification Lentinus edodes (Berk. ) Sing Plants Disease Research Fields Saccharides Cancer	Others
Lentinan is purified β-glucan from Shiitake mushrooms. Lentinan has been approved as a biological response modifier for gastric cancer in Japan .

HY-W015114

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-N7075

Inulin 2 Publications Verification	Structural Classification Classification of Application Fields Source classification Metabolic Disease Plants Compositae Endogenous metabolite Sophora tomentosa L. Human Gut Microbiota Metabolites Polysaccharides Microorganisms Disease Research Fields Saccharides	Endogenous Metabolite
Inulin is a storage polysaccharide and belongs to a group of non-digestible carbohydrates, fructan. Inulin is from plants of the Compositae and Lilialiaceaes families, often used as a prebiotic, fat replacer, sugar replacer, texture modifier, plays beneficial role in gastric .

HY-N7438

Mogroside VI A	Triterpenes Classification of Application Fields Terpenoids Source classification Other Diseases Cucurbitaceae Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Sweeteners Food Research	Others
Mogroside VI A, an isomer of Mogroside VI isolated from Luo Han Guo, exerts sweetness property. Mogroside VI A can be used for sweetener and/or taste modifier research .

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Structural Classification Microorganisms Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-112624C

Dextran (MW 40000)	Structural Classification Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields Saccharides	Biochemical Assay Reagents Endogenous Metabolite
Dextran (MW 40000) is a complex carbohydrate polymer consisting of glucose molecules linked by glycosidic bonds. Dextran has excellent solubility in water, making it useful as a viscosity modifier or stabilizer in foods, paints and adhesives. In the biomedical field, dextran is often used as a plasma expander because of its ability to increase blood volume when administered intravenously. It can also be modified to create dextran-based drug delivery systems, such as targeted nanoparticles.

HY-113039R

L-2-Hydroxyglutaric acid (Standard) (S)-2-Hydroxyglutaric acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid (Standard) is the analytical standard of L-2-Hydroxyglutaric acid. This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-W015114R

L-2-Hydroxyglutaric acid disodium (Standard) (S)-2-Hydroxyglutaric acid disodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite
L-2-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of L-2-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

Species:	Human (11)
Tag:	SUMO (1) His (10) Strep (3) Tag Free (1) GST (1)
Source:	HEK293 (1) Sf9 insect cells (4) E. coli (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P71346

	SUMO3 Protein, Human (HEK293, His) Small ubiquitin-related Modifier 3; SUMO-3; SMT3 homolog 1; SUMO-2; Ubiquitin-like protein SMT3A; Smt3A	Human	HEK293
	SUMO3 is a multifunctional ubiquitin-like protein that can attach to target lysines, acting as a monomer or forming lysine-linked polymers. Unlike ubiquitin, SUMO3 is not involved in protein degradation; instead, it may counteract ubiquitin degradation. SUMO3 Protein, Human (HEK293, His) is the recombinant human-derived SUMO3 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of SUMO3 Protein, Human (HEK293, His) is 91 a.a., with molecular weight of ~21.0 kDa.

HY-P72096

	ATP5F1A Protein, Human (His-SUMO) ATP synthase alpha chain; ATP synthase alpha chain; mitochondrial; ATP synthase subunit alpha; ATP synthase subunit alpha mitochondrial; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit 1; cardiac muscle; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; 1; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; isoform 1; cardiac muscle; ATP synthase; H+ transporting; mitochondrial F1 complex; alpha subunit; isoform 2; non-cardiac muscle-like 2; ATP sythase F1 ATPase; alpha subunit; ATP5A; Atp5a1; ATP5AL2; ATPA_HUMAN; ATPM; Epididymis secretory sperm binding protein Li 123m; hATP1; HEL-S-123m; MC5DN4; mitochondrial; Mitochondrial ATP synthetase; Mitochondrial ATP synthetase oligomycin resistant; Modifier of Min 2; Modifier of Min 2 mouse homolog; Modifier of Min 2; mouse; homolog of; MOM2; OMR; ORM; OTTHUMP00000163475	Human	E. coli
	ATP5F1A is an important component of mitochondrial ATP synthase (complex V) that coordinates ATP production from ADP by utilizing the transmembrane proton gradient. As part of the F-type ATPase, the α and β subunits of ATP5F1A form the catalytic core to achieve ATP hydrolysis. ATP5F1A Protein, Human (His-SUMO) is the recombinant human-derived ATP5F1A protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of ATP5F1A Protein, Human (His-SUMO) is 510 a.a., with molecular weight of ~71.2 kDa.

HY-P70974

	SUMO2 Protein, Human (His) Small Ubiquitin-Related Modifier 2; SUMO-2; HSMT3; SMT3 homolog 2; SUMO-3; Sentrin-2; Ubiquitin-Like Protein SMT3A; Smt3A; SUMO2; SMT3A; SMT3H2	Human	E. coli
	Small ubiquitin-related modifier 2 (SUMO2) is a ubiquitin-like protein that covalently attached to proteins as part of post-translational modification system. SUMO2 is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, DNA replication and repair, mitosis, signal transduction and protein stability. SUMO2 Protein, Human (His) is the recombinant human-derived SUMO2 protein, expressed by E. coli , with N-6*His labeled tag. The total length of SUMO2 Protein, Human (His) is 93 a.a., with molecular weight of ~17.0 kDa.

HY-P701492

	UFC1 Protein, Human (Sf9, His, Strep) UFC1; Ubiquitin-fold Modifier-conjugating enzyme 1; Ufm1-conjugating enzyme 1	Human	Sf9 insect cells
	The UFC1 protein catalyzes the second step of ufmylation, accepting UFM1 from UBA5 and forming an intermediate with UFM1. Ufmylation is involved in reticulophagy and interacts with UBA5, UFL1, and UFM1. It also interacts with KIRREL3. UFC1 Protein, Human (Sf9, His, Strep) is the recombinant human-derived UFC1 protein, expressed by Sf9 insect cells , with N-Strep, N-8*His labeled tag. The total length of UFC1 Protein, Human (Sf9, His, Strep) is 166 a.a., .

HY-P70997

	SUMO1 Protein, Human (His) Small Ubiquitin-Related Modifier 1; SUMO-1; GAP-Modifying Protein 1; GMP1; SMT3 Homolog 3; Sentrin; Ubiquitin-Homology Domain Protein PIC1; Ubiquitin-Like Protein SMT3C; Smt3C; Ubiquitin-Like Protein UBL1; SUMO1; SMT3C; SMT3H3; UBL1	Human	E. coli
	SUMO1 Protein is a member of the SUMO (small ubiquitin-like modifier) protein family. SUMO1 binds to target proteins as part of a post-translational modification system. It is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. SUMO1 also regulates the function of several proteins via non-covalent interactions. SUMO1 Protein, Human (His) is the recombinant human-derived SUMO1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of SUMO1 Protein, Human (His) is 101 a.a., with molecular weight of 17-19 kDa.

HY-P74485

	UBA1 Protein, Human (sf9, His-GST) 1 Publications Verification Ubiquitin-like Modifier-activating enzyme 1; Protein A1S9; UBA1; A1S9T; UBE1	Human	Sf9 insect cells
	The UBA1 protein initiates ubiquitin conjugation, marking proteins for degradation in the ubiquitin-proteasome system. UBA1 Protein, Human (sf9, His-GST) is the recombinant human-derived UBA1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of UBA1 Protein, Human (sf9, His-GST) is 1057 a.a., with molecular weight of ~130 kDa.

HY-P71395

	UBA5 Protein, Human (His) Ubiquitin-like Modifier-activating enzyme 5; ThiFP1; UFM1-activating enzyme; Ubiquitin-activating enzyme E1 domain-containing protein 1; UBE1DC1; UBA5	Human	E. coli
	The UBA5 protein activates UFM1 in ufmylation, linking the C-terminal glycine residue of UFM1 to a cysteine residue in E1. UBA5 Protein, Human (His) is the recombinant human-derived UBA5 protein, expressed by E. coli , with N-6*His labeled tag. The total length of UBA5 Protein, Human (His) is 404 a.a., with molecular weight of 14 & 40-60 kDa, respectively.

HY-P79454

	ISG15 E1/UBE1L Protein, Human (sf9, His, Strep) Ubiquitin-like Modifier-activating enzyme 7; UBA7; Ubiquitin-activating enzyme 7; D8; Ubiquitin-activating enzyme E1 homolog; UBE1L; UBE2	Human	Sf9 insect cells
	The ISG15 E1/UBE1L protein initiates ubiquitination by adenylating the C-terminal glycine of ubiquitin with ATP to form a thioester bond with its cysteine residue. This produces ubiquitin-E1 thioester and free AMP. ISG15 E1/UBE1L Protein, Human (sf9, His, Strep) is the recombinant human-derived ISG15 E1/UBE1L protein, expressed by Sf9 insect cells , with N-8*His, N-Strep labeled tag. The total length of ISG15 E1/UBE1L Protein, Human (sf9, His, Strep) is 1011 a.a., .

HY-P701353

	UBE1L2/UBA6 Protein, Human (Sf9, His, Strep) UBA6; Ubiquitin-like Modifier-activating enzyme 6; Ubiquitin-activating enzyme 6; Monocyte protein 4; MOP-4; Ubiquitin-activating enzyme E1-like protein 2; E1-L2	Human	Sf9 insect cells
	The ubiquitin E1 enzyme initiates ubiquitination by adenylating ubiquitin with ATP and forming a thioester bond with the E1 enzyme. It exhibits specificity for ubiquitin and excludes ubiquitin-like peptides. UBE1L2/UBA6 Protein, Human (Sf9, His, Strep) is the recombinant human-derived UBE1L2/UBA6 protein, expressed by Sf9 insect cells , with N-Strep, N-8*His labeled tag. The total length of UBE1L2/UBA6 Protein, Human (Sf9, His, Strep) is 1051 a.a., .

HY-P70909

	MAP1LC3B Protein, Human Microtubule-associated proteins 1A/1B light chain 3B; Autophagy-related protein LC3 B; Autophagy-related ubiquitin-like Modifier LC3 B; MAP1 light chain 3-like protein 2; MAP1A/MAP1B light chain 3 B; MAP1A/MAP1B LC3 B; Microtubule-associated protein 1 light cha	Human	E. coli
	MAP1LC3B is a key ubiquitin-like modifier essential for the formation of autophagosome vacuoles, which maintains cellular homeostasis. In mitophagy, it regulates mitochondrial number, suppresses reactive oxygen species and ensures energy efficiency. MAP1LC3B Protein, Human is the recombinant human-derived MAP1LC3B protein, expressed by E. coli , with tag free. The total length of MAP1LC3B Protein, Human is 125 a.a., with molecular weight of ~16.15 kDa.

HY-P70916

	MAP1LC3A Protein, Human (His) Microtubule-Associated Proteins 1A/1B Light Chain 3A; Autophagy-Related Protein LC3 A; Autophagy-Related Ubiquitin-Like Modifier LC3 A; MAP1 Light Chain 3-Like Protein 1; MAP1A/MAP1B Light Chain 3 A; MAP1A/MAP1B LC3 A; Microtubule-Associated Protein 1 Light Cha	Human	E. coli
	MAP1LC3A is a key ubiquitin-like modifier essential for autophagosome vacuole formation, ensuring cellular homeostasis. As part of the GABARAP/GATE-16 subfamily, it plays a crucial role in late autophagosome maturation. MAP1LC3A Protein, Human (His) is the recombinant human-derived MAP1LC3A protein, expressed by E. coli , with C-6*His labeled tag. The total length of MAP1LC3A Protein, Human (His) is 121 a.a., with molecular weight of ~16.0 kDa.

Cat. No.	Product Name	Chemical Structure

HY-109101S

Risdiplam-d4
Risdiplam-d₄ is deuterium labeled Risdiplam. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1].

HY-145989S

Aminobenzenesulfonic auristatin E-d8
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].

HY-109101AS1

Risdiplam-hydroxylate-d3
Risdiplam-hydroxylate-d₃ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-109101AS2

Risdiplam-hydroxylate-d6
Risdiplam-hydroxylate-d₆ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-13619S

Efaproxiral-d6
Efaproxiral-d₆ is the deuterium labeled Efaproxiral. Efaproxiral (RSR13) is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy[1][2].

HY-B0180S

Imiquimod-d6
Imiquimod-d₆ is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

HY-B0180S1

Imiquimod-d9
Imiquimod-d₉ is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].

Cat. No.	Product Name	Application	Reactivity

HY-P80707

HP1 gamma Antibody (YA733) CBX3; Chromobox protein homolog 3; HECH; Heterochromatin protein 1 homolog gamma; HP1 gamma; Modifier 2 protein	WB, IHC-F, IHC-P, ICC/IF, IP	Mouse, Human, Monkey, Hamster, Rat
HP1 gamma Antibody (YA733) is a non-conjugated and Mouse origined monoclonal antibody about 21 kDa, targeting to HP1 gamma (5G10). It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Mouse, Human, Monkey, Hamster, Rat.

HY-P81832

UFM1 Antibody (YA1577)

Ubiquitin-fold Modifier 1; C13orf20
WB, IHC-P, IP Human, Mouse

HY-P80365

*Ubiquitin-like modifier-activating enzyme 1 Antibody*	WB, ICC/IF, IHC-P, FC	Human, Mouse
Ubiquitin-like modifier-activating enzyme 1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 118 kDa, targeting to Ubiquitin-like modifier-activating enzyme 1. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

HY-P80905

SUMO1 Antibody (YA047) SUMO1; SMT3C; SMT3H3; UBL1; OK/SW-cl.43; Small ubiquitin-related Modifier 1; SUMO-1; GAP-modifying protein 1; GMP1; SMT3 homolog 3; Sentrin; Ubiquitin-homology domain protein PIC1; Ubiquitin-like protein SMT3C; Smt3C; Ubiquitin-like protein	WB, IHC-P	Human, Mouse, Rat
SUMO1 Antibody (YA047) is a non-conjugated and Rabbit origined monoclonal antibody, targeting to SUMO1. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P81662

GCLM Antibody (YA1407) GCLM; GLCLR; Glutamate--cysteine ligase regulatory subunit; GCS light chain; Gamma-ECS regulatory subunit; Gamma-glutamylcysteine synthetase regulatory subunit; Glutamate--cysteine ligase Modifier subunit	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat

HY-P82072

E1 Ubiquitin Activating Enzyme Antibody (YA1817) UBA1; A1S9T; UBE1; Ubiquitin-like Modifier-activating enzyme 1; Protein A1S9; Ubiquitin-activating enzyme E1	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat

HY-P81226

LC3 Antibody Autophagy related protein LC3 A; Autophagy related protein LC3 B; Autophagy related ubiquitin like Modifier LC3 A; Autophagy related ubiquitin like Modifier LC3 B; MAP1 light chain 3 like protein 1; MAP1 light chain 3 like protein 2; MAP1A/1B light chain 3 A; MAP1A/1B light chain 3 B; MAP1A/1BLC3; MAP1A/MAP1B LC3 A; MAP1A/MAP1B LC3 B; MAP1ALC3; MAP1BLC3; MAP1LC3A; MAP1LC3B; Microtubule associated protein 1 light chain 3 alpha; Microtubule associated protein 1 light chain 3 beta; Microtubule associated proteins 1A/1B light chain 3; Microtubule associated proteins 1A/1B light chain 3A; Microtubule associated proteins 1A/1B light chain 3B; MLP3A_HUMAN.	WB; ELISA; IHC-P; IHC-F; Flow-Cyt; IF	Human, Rat(predicted: Mouse, Chicken, Dog, Pig, Cow, Horse, Sheep, Goat)
LC3 Antibody is an unconjugated, approximately 14/16 kDa, rabbit-derived, anti-LC3 polyclonal antibody. LC3 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, rat, and predicted: mouse, chicken, dog, pig, cow, horse, sheep, goat background without labeling.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks